S.A. Mason LLC Apellis Pharmaceuticals, Inc. Transaction History

S.A. Mason LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$46.59 - $66.96 $66,856 - $96,087	-1,435 Reduced 60.81%	925 $61,000
Q3 2022 Oct 20, 2022	SELL	$44.76 - $69.66 $35,808 - $55,728	-800 Reduced 25.32%	2,360 $161,000
Q2 2022 Jul 07, 2022	BUY	$35.07 - $59.21 $14,554 - $24,572	415 Added 15.12%	3,160 $143,000
Q1 2022 May 12, 2022	SELL	$35.46 - $54.12 $49,998 - $76,309	-1,410 Reduced 33.94%	2,745 $139,000
Q3 2021 Oct 12, 2021	BUY	$31.4 - $69.84 $108,173 - $240,598	3,445 Added 485.21%	4,155 $137,000
Q2 2021 Jul 07, 2021	BUY	$40.9 - $64.9 $29,039 - $46,079	710 New	710 $45,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of S.A. Mason LLC, based on Form 13F filings with the SEC.

Stay updated on S.A. Mason LLC with notifications on news.